Long-term Follow-up Study of Patients Receiving CAR-T Cells

Medical College of Wisconsin

Status: Enrolling

Conditions: Multiple Myeloma; Lymphomas Non-Hodgkin's B-Cell; Follicular Lymphoma; Mantle Cell Lymphoma; Lymphoma, Small Lymphocytic; Central Nervous System Lymphoma; Chronic Lymphocytic Leukemia; Burkitt Lymphoma; Diffuse Large B Cell Lymphoma

Treatments: Other: Long-Term Follow-Up of Participants who Received CAR-T cells

Study type: Observational

Funder types: Other

Identifiers

NCT03375619

PRO30317

Details and patient eligibility

About

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following:

Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Full description

The objective is to follow participants receiving CAR-T cells from years 2 to 15 post-treatment for persistence of CAR-T cells, development of secondary malignancies, or other medical complications.

Enrollment: 500 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All participants who enrolled in a CAR-T study at Froedtert Hospital & the Medical College of Wisconsin.

Exclusion criteria

• There are no exclusion criteria for this study.

Trial design

500 participants in 1 patient group

Participants who received CAR-T cells.

Description:

Participants who received CAR-T cells at Froedtert Hospital \& the Medical College of Wisconsin in clinical trials (e.g., NCT05976555, NCT05094206, NCT05990465, NCT03019055 or NCT04186520).

Treatment:

Other: Long-Term Follow-Up of Participants who Received CAR-T cells